{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:37:02Z","timestamp":1763642222559},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To identify clinical and pharmacogenetic determinants of efficacy and toxicity of methotrexate (MTX) in juvenile idiopathic arthritis (JIA) over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A cohort of 119 consecutive patients with JIA treated with MTX was reviewed. The Juvenile Arthritis Disease Activity Score including 71 joints was used to measure disease activity. Nonresponders were patients who did not reach a minimum of 30% improvement after 6 months of treatment or were switched to biologic drugs in the first 6 months because of inefficacy. All adverse events (AE) were noted. Genotyping of single-nucleotide polymorphisms (SNP) in the genes coding for MTX transporters, folate pathway, and adenosine pathway was performed using real-time PCR methods. Univariate and multivariable penalized logistic and Cox regression were used to analyze data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Thirty patients (25.8%) were defined as nonresponders and 55 (47.2%) were switched to biologics during the followup. Sixty-five patients (54.5%) reported AE in a total of 405 patient-years, and 10 patients (8.4%) discontinued MTX because of AE. <jats:italic>AMPD1<\/jats:italic> rs17602729 and <jats:italic>MTHFD1<\/jats:italic> rs2236225 were associated with gastrointestinal AE while the latter together with <jats:italic>MTRR<\/jats:italic> rs1801394 also demonstrated associations with developing hepatoxicity. <jats:italic>MTHFR<\/jats:italic> rs1801131, <jats:italic>ABCG2<\/jats:italic> rs2231137, wild-type of <jats:italic>MTR<\/jats:italic> rs1805087, and wild-type of <jats:italic>ABCC2<\/jats:italic> rs2273697 were identified as potential markers for discontinuing MTX treatment because of AE. <jats:italic>MTHFR<\/jats:italic> rs1801133, <jats:italic>MTRR<\/jats:italic> rs1801394, and <jats:italic>ABCC2<\/jats:italic> rs2273697 were associated with switching to biologics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>SNP in different MTX metabolic pathways influence treatment with MTX. Genetic variability is a better marker for toxicity than efficacy.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160950","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:20:22Z","timestamp":1496362822000},"page":"1216-1223","source":"Crossref","is-referenced-by-count":17,"title":["Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"44","author":[{"given":"Mojca","family":"Zajc Avramovi\u010d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nata\u0161a","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meta","family":"Accetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Lusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadej","family":"Av\u010din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"2018112909371554000_44.8.1216.1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2018112909371554000_44.8.1216.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"2018112909371554000_44.8.1216.3","doi-asserted-by":"publisher","DOI":"10.2174\/138920009789375414"},{"key":"2018112909371554000_44.8.1216.4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328329c79d"},{"key":"2018112909371554000_44.8.1216.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0521-7"},{"key":"2018112909371554000_44.8.1216.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111567"},{"key":"2018112909371554000_44.8.1216.7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/pgs.12.214","article-title":"Methotrexate pharmacogenetics in rheumatoid arthritis: a status report","volume":"14","author":"Malik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"2018112909371554000_44.8.1216.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200942"},{"key":"2018112909371554000_44.8.1216.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111593"},{"key":"2018112909371554000_44.8.1216.10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1546-0096-12-51","article-title":"Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review","volume":"12","author":"van Dijkhuizen","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"2018112909371554000_44.8.1216.11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12969-015-0002-3","article-title":"Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study","volume":"13","author":"van Dijkhuizen","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"2018112909371554000_44.8.1216.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.24087"},{"key":"2018112909371554000_44.8.1216.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091427"},{"key":"2018112909371554000_44.8.1216.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03814.x"},{"key":"2018112909371554000_44.8.1216.15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrrheum.2014.140","article-title":"Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?","volume":"10","author":"Schmeling","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2018112909371554000_44.8.1216.16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00296-014-3131-y","article-title":"5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis","volume":"35","author":"Pastore","year":"2015","journal-title":"Rheumatol Int"},{"key":"2018112909371554000_44.8.1216.17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/tpj.2014.3","article-title":"Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases","volume":"14","author":"Cobb","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"2018112909371554000_44.8.1216.18","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790112683"},{"key":"2018112909371554000_44.8.1216.19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23074"},{"key":"2018112909371554000_44.8.1216.20","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909371554000_44.8.1216.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2018112909371554000_44.8.1216.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.34373"},{"key":"2018112909371554000_44.8.1216.23","first-page":"789","article-title":"Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis","volume":"33","author":"Wallace","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909371554000_44.8.1216.24","unstructured":"U.S. Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE) version 4.03. [Internet. Accessed April 10, 2017.] Available from: evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"2018112909371554000_44.8.1216.25","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2007"},{"key":"2018112909371554000_44.8.1216.26","unstructured":"Team RC . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2015."},{"key":"2018112909371554000_44.8.1216.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.9.975"},{"key":"2018112909371554000_44.8.1216.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08876.x"},{"key":"2018112909371554000_44.8.1216.29","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000173616.81928.44"},{"key":"2018112909371554000_44.8.1216.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.30367"},{"key":"2018112909371554000_44.8.1216.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.146191"},{"key":"2018112909371554000_44.8.1216.32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-016-0071-y","article-title":"Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis","volume":"14","author":"Scheuern","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"2018112909371554000_44.8.1216.33","first-page":"1832","article-title":"Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis","volume":"32","author":"Schmeling","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909371554000_44.8.1216.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.22129"},{"key":"2018112909371554000_44.8.1216.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.24179"},{"key":"2018112909371554000_44.8.1216.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"2018112909371554000_44.8.1216.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080576"},{"key":"2018112909371554000_44.8.1216.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2645-8"},{"key":"2018112909371554000_44.8.1216.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700808"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:19:29Z","timestamp":1543519169000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,1]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.3899\/jrheum.160950"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160950","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}